2014


To access this material please log in or register

Register Authorize
2014/№2

Protective therapy for atrial fibrillation with a late potassium channel blocker (pilot study)

Tatarsky B. A.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: late sodium-channel blockers, treatment, ranolazine, atrial fibrillation

DOI: 10.18087/rhj.2014.2.1873

Background. Appropriate choice of anti-arrhythmic therapy reduces the risk associated with this therapy. The choice is especially difficult in treatment of atrial fibrillation (AF) in patients with CHF. Aim. To evaluate the efficacy of ranolazine as a possible choice of protective therapy in CHF patients with preserved systolic function and persistent AF. Materials and methods. 18 patients aged 40 to 67 years with documented, frequent episodes of recurrent AF and FC II–III CHF were evaluated. Recurrent AF persisted despite the anti-arrhythmic treatment. Ranolazine 500 mg bid was administered for 3 days prior to cardioversion (CV). If the therapy was well tolerated the dose was increased to 1000 mg bid for the entire follow-up period. Results. At 6 months, a response to ranolazine was observed in 12 of 14 patients. At the end of follow-up period, stable sinus rhythm was observed in 10 (71 %) patients; one patient had rare episodes of spontaneous AF arrest; three patients developed persistent, recurrent AF. After one year of the ranolazine treatment, a protective effect was observed in 11 (73 %) of 15 patients, who have restored their heart rhythm after elective CV. Conclusion. The ranolazine treatment can be protective in AF without pro-arrhythmic complications. Additional large-scale, randomized studies (including direct comparative studies) are required for evaluation of ranolazine efficacy and safety.
  1. Wann LS, Curtis AB, January CT et al. 2011 ACCF / AHA / HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8 (1):157–176.
  2. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008;10 (6):647–665.
  3. Sullivan S, Orme M, Morais E et al. Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis. Int J Cardiol. 2013;165 (2):229–236.
  4. de Denus S, Sanoski CA, Carlsson J et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165 (3):258–262.
  5. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011. Доступно на: http://scardio.ru / content / Guidelines / Rekomendations_fibrillyacia_predserdii_2012.pdf
  6. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiologic effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110 (8):904–910.
  7. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44 (2):192–199.
  8. Sicouri S, Glass A, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5 (7):1019–1026.
  9. Burashnikov A, Di Diego JM, Zygmunt AC et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116 (13):1449–1457.
  10. Татарский Б. А. Использование блокатора поздних натриевых каналов при купировании фибрилляции предсердий (пилотное исследование. Сердце. 2013;12 (2):129–133.
  11. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  12. Camm AJ, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (deve­loped with the special contribution of the European Heart Rhythm Association, endorsed by the European Association for Cardio-Thoracic Surgery). Eur Heart J. 2010;31 (19):2369–2429.
  13. Van Gelder IC, Hagens VE, Bosker HA et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl J Med. 2002;347 (23):1834–1840.
  14. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I (Na) using ranolazine. J Cardiovasc Pharmacol. 2009;54 (4):279–286.
  15. Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 2003;107 (18):2355–2360.
  16. Antzelevitch C, Burashnikov A, Sicouri S. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8 (8):1281–1290.
  17. Murdock D, Overton N, Kersten M. et al. The effect of ranolazine on maintaining sinus rhythm in patient with resistant atrial fibrillation. Indian Pacing Electrophysiol J.2008;8 (3):175–181.
  18. Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J Pharmacol Sci. 2006;100 (5):315–322.
  19. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 (Suppl 4):iv6‑iv14.
Tatarsky B. A. Protective therapy for atrial fibrillation with a late potassium channel blocker (pilot study). Russian Heart Journal. 2014;76 (2):123–128

To access this material please log in or register

Register Authorize
Ru En